v3.25.4
Fair Value Measurement - Summary of Fair Value Measurement on Recurring Basis, Unobservable Input Reconciliation (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
IntelGenx Subsequent DIP Loan Commitment    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Beginning Balance $ 0 $ 0
Initial fair value of instrument   680
Change in fair value   0
Additional Warrants received   0
Reduction in commitment   (680)
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Additional Warrants Recevied   0
Consideration for acquisition   0
Ending Balance   0
Contingent Consideration Liabilities - Related Parties    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Beginning Balance [1] 110  
Change in fair value [1] (6)  
Conversion of convertible notes [1] 0  
Ending Balance [1] 104 110
New NV Notes Conversion Feature    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Beginning Balance 2,611 2,385
Initial fair value of instrument   3,590
Change in fair value 20,249 (3,363)
Additional Warrants received   0
Reduction in commitment   0
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Additional Warrants Recevied   0
Consideration for acquisition   0
Conversion of convertible notes (22,860)  
Ending Balance 0 2,611
Beckley Psytech Additional Warrants    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Beginning Balance 2,783 0
Initial fair value of instrument   2,645
Change in fair value (2,783) 1,676
Additional Warrants received   (1,538)
Reduction in commitment   0
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Additional Warrants Recevied   (1,538)
Consideration for acquisition   0
Conversion of convertible notes 0  
Ending Balance 0 2,783
IntelGenx Convertible Notes Receivable    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Beginning Balance 0 11,202
Initial fair value of instrument   8,243
Change in fair value   (13,729)
Additional Warrants received   0
Reduction in commitment   0
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Additional Warrants Recevied   0
Consideration for acquisition   (5,715)
Ending Balance   0
IntelGenx Investments Held at Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Beginning Balance [2] 0 6,124
Initial fair value of instrument [2]   420
Change in fair value [2]   (6,544)
Additional Warrants received [2]   0
Reduction in commitment [2]   0
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Additional Warrants Recevied [2]   0
Consideration for acquisition [2]   0
Ending Balance [2]   0
Contingent Consideration Liability - Related Parties [Member]    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Beginning Balance [3] 110 620
Initial fair value of instrument [3]   0
Change in fair value [3]   (510)
Additional Warrants received [3]   0
Reduction in commitment [3]   (0)
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Additional Warrants Recevied [3]   0
Consideration for acquisition [3]   0
Ending Balance [3]   110
Contingent Consideration Liabilities    
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
Beginning Balance [5] 212 [4] 1,637
Initial fair value of instrument [5]   0
Change in fair value (7) [4] (1,425) [5]
Additional Warrants received [5]   0
Reduction in commitment [5]   0
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Additional Warrants Recevied [5]   0
Consideration for acquisition [5]   0
Conversion of convertible notes [4] 0  
Ending Balance [4] $ 205 $ 212 [5]
[1] Includes Perception milestone based contingent consideration liability.
[2] Includes, Initial Warrants, Additional Unit Awards, 2023 Initial Warrants, 2023 Subsequent Warrants, and Call Option Units.
[3] Includes Perception's milestone-based contingent consideration liability.
[4] Includes contingent consideration liability related to DemeRx IB Stock Purchase and contingent consideration liability related to the TryptageniX research and development milestone success fee payments and royalties payments.
[5] Includes the contingent consideration liability related to DemeRx IB Stock Purchase and the contingent consideration liability related to the TryptageniX
research and development milestone success fee payments and royalties payments.